Noroviruses (NoVs) account for the majority of diagnosed cases of viral acute gastroenteritis worldwide. Virus-like particle (VLP)-based vaccines against NoV are currently under development. Serum antibodies that block the binding of NoV VLPs to histo-blood group antigens, the putative receptors for NoV, correlate with protection against NoV infection. The role of functional mucosal antibodies in protection is largely unknown, even though the intestinal mucosa is the entry port for NoV. Balb/c mice were immunized intramuscularly (IM) or intranasally (IN) with NoV GII.4 VLPs, and systemic and mucosal blocking antibody responses were studied. IN immunization elicited NoV-specific serum and mucosal IgG and IgA antibodies, whereas IM immunized animals completely lacked IgA. Both immunization routes induced similar blocking activity in serum but only IN route generated blocking antibodies in mucosa. The level of IgA in the mucosal (nasal) lavages strongly correlated (r = 0.841) with the blocking activity, suggesting that IgA, but not IgG, is the major NoV blocking antibody on mucosal surfaces. The results indicate that only mucosal immunization route induces the development of functional anti-NoV IgA on mucosal surface.
Get full access to this article
View all access options for this article.
References
1.
AmuguniJH, LeeS, KersteinKO, et al.Sublingually administered Bacillus subtilis cells expressing tetanus toxin C fragment induce protective systemic and mucosal antibodies against tetanus toxin in mice. Vaccine, 2011; 29:4778–4784.
2.
AtmarRL, BernsteinDI, HarroCD, et al.Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med, 2011; 365:2178–2187.
3.
AtmarRL, BernsteinDI, LyonGM, et al.Serological correlates of protection against a GII.4 norovirus. Clin Vaccine Immunol, 2015; 22:923–929.
4.
BernsteinDI, AtmarRL, LyonGM, et al.Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. J Infect Dis, 2014; 211:870–878.
5.
BlazevicV, LappalainenS, NurminenK, et al.Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis. Vaccine, 2011; 29:8126–8133.
6.
BokK, and GreenKY. Norovirus gastroenteritis in immunocompromised patients. N Engl J Med, 2012; 367:2126–2132.
7.
BrandtzaegP. Secretory IgA: designed for anti-microbial defense. Front Immunol, 2013; 4:222.
8.
HarringtonPR, LindesmithL, YountB, et al.Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J Virol, 2002; 76:12335–12343.
9.
HuangP, FarkasT, ZhongW, et al.Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J Virol, 2005; 79:6714–6722.
10.
HuhtiL, BlazevicV, NurminenK, et al.A comparison of methods for purification and concentration of norovirus GII-4 capsid virus-like particles. Arch Virol, 2010; 155:1855–1858.
11.
HurEM, PatelSN, ShimizuS, et al.Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice. Blood, 2012; 120:4571–4582.
12.
JohnsonPC, MathewsonJJ, DuPontHL, et al.Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults. J Infect Dis, 1990; 161:18–21.
13.
JonesMK, GrauKR, CostantiniV, et al.Human norovirus culture in B cells. Nat Protoc, 2015; 10:1939–1947.
14.
KerrMA. The structure and function of human IgA. Biochem J, 1990; 271:285–296.
15.
KowalzikF, Riera-MontesM, VerstraetenT, et al.The burden of norovirus disease in children in the European Union. Pediatr Infect Dis J, 2015; 34:229–234.
16.
KronemanA, VegaE, VennemaH, et al.Proposal for a unified norovirus nomenclature and genotyping. Arch Virol, 2013; 158:2059–2068.
17.
LappalainenS, PastorAR, TamminenK, et al.Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo. Hum Vaccin Immunother, 2014; 10:2039–2047.
18.
LindesmithL, MoeC, MarionneauS, et al.Human susceptibility and resistance to Norwalk virus infection. Nat Med, 2003; 9:548–553.
19.
LindesmithLC, BeltramelloM, SwanstromJ, et al.Serum immunoglobulin A cross-strain blockade of human noroviruses. Open Forum Infect Dis, 2015; 2:ofv084.
20.
LindesmithLC, DonaldsonE, LeonJ, et al.Heterotypic humoral and cellular immune responses following Norwalk virus infection. J Virol, 2010; 84:1800–1815.
21.
LoBueAD, ThompsonJM, LindesmithL, et al.Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge. J Virol, 2009; 83:3212–3227.
22.
MalmM, TamminenK, VesikariT, et al.Comparison of intramuscular, intranasal and combined administration of norovirus virus-like particle subunit vaccine candidate for induction of protective immune responses in mice. J Clin Cell Immunol, 2015; 6:284.
23.
MarionneauS, Cailleau-ThomasA, RocherJ, et al.ABH and Lewis histo-blood group antigens, a model for the meaning of oligosaccharide diversity in the face of a changing world. Biochimie, 2001; 83:565–573.
24.
MarionneauS, RuvoenN, Le Moullac-VaidyeB, et al.Norwalk virus binds to histo-blood group antigens present on gastroduodenal epithelial cells of secretor individuals. Gastroenterology, 2002; 122:1967–1977.
25.
MazanecMB, NedrudJG, LiangXP, et al.Transport of serum IgA into murine respiratory secretions and its implications for immunization strategies. J Immunol, 1989; 142:4275–4281.
26.
NurminenK, BlazevicV, HuhtiL, et al.Prevalence of norovirus GII-4 antibodies in Finnish children. J Med Virol, 2011; 83:525–531.
27.
ParraGI, and GreenKY. Sequential gastroenteritis episodes caused by 2 norovirus genotypes. Emerg Infect Dis, 2014; 20:1016–1018.
28.
PatelMM, WiddowsonMA, GlassRI, et al.Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg Infect Dis, 2008; 14:1224–1231.
29.
RamaniS, NeillFH, OpekunAR, et al.Mucosal and cellular immune responses to Norwalk virus. J Infect Dis, 2015; 212:397–405.
30.
ReeckA, KavanaghO, EstesMK, et al.Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis, 2010; 202:1212–1218.
31.
SinghBK, LeutholdMM, and HansmanGS. Human noroviruses' fondness for histo-blood group antigens. J Virol, 2015; 89:2024–2040.
32.
SundararajanA, SangsterMY, FreyS, et al.Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine. Vaccine, 2015; 33:568–576.
33.
TamminenK, HuhtiL, KohoT, et al.A comparison of immunogenicity of norovirus GII-4 virus-like particles and P-particles. Immunology, 2012; 135:89–99.
34.
TamminenK, LappalainenS, HuhtiL, et al.Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice. PLoS One, 2013; 8:e70409.
35.
TrivediTK, DeSalvoT, LeeL, et al.Hospitalizations and mortality associated with norovirus outbreaks in nursing homes, 2009–2010. JAMA, 2012; 308:1668–1675.
36.
VegaE, BarclayL, GregoricusN, et al.Genotypic and epidemiologic trends of norovirus outbreaks in the United States, 2009 to 2013. J Clin Microbiol, 2014; 52:147–155.
37.
VelasquezLS, ShiraS, BertaAN, et al.Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine. Vaccine, 2011; 29:5221–5231.
38.
VerhoefL, HewittJ, BarclayL, et al.Norovirus genotype profiles associated with foodborne transmission, 1999–2012. Emerg Infect Dis, 2015; 21:592–599.
